Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MIST Trial Reveals Mixed Results For PFO Treatment Of Migraine

This article was originally published in The Gray Sheet

Executive Summary

Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
Advertisement

Related Content

Enrollment Headaches Cause NMT To Drop Migraine Trial
Enrollment Headaches Cause NMT To Drop Migraine Trial
Next Generation Of PFO Closure Systems Aim For Less Device Exposure
Next Generation Of PFO Closure Systems Aim For Less Device Exposure
NMT Medical To Redesign PFO Trial After Problems With MIST I
St. Jude Stock Tumbles On T-Wave Alternans Coverage; Index Continues Slide
NMT Medical, AGA Medical settle
Leading Neurologist Remains Skeptical In Run-Up To NMT’s MIST Trial Results
Leading Neurologist Remains Skeptical In Run-Up To NMT’s MIST Trial Results
St. Jude Expects Easy Enrollment In New PFO Study For Migraines
Advertisement
UsernamePublicRestriction

Register

MT023340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel